Breaking News

Ampersand Acquires Nektar Therapeutics’ PEG Reagent Manufacturing Biz

Launches newly rebranded Gannet BioChem.

Author Image

By: Charlie Sternberg

Associate Editor

Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, has closed its acquisition of Nektar Therapeutics’ PEGylation reagent manufacturing business.   The new Ampersand portfolio company will be branded Gannet BioChem and will continue to operate out of its state-of-the-art facility in Huntsville, Alabama. Ampersand also acquired Biologos LLC, a full-service manufacturer of custom and standard cell culture ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters